CStone Pharmaceuticals Stock Deutsche Boerse AG
Stocks
PH4
KYG2588M1006
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5050 EUR | +4.27% |
|
-1.60% | -11.40% |
| 06-12 | CStone Pharmaceuticals Drug Receives Ethics Approval in Australia | MT |
| 06-11 | Cstone Presents Clinical Data for Cs2009 Trispecific Antibody At Asco 2026 | CI |
| Market Cap | 6.49B 958M 837M 774M 723M 1.36B 90.54B 1.37B 9.2B 3.58B 44.51B 3.6B 3.52B 155B | P/E 2026 * |
-305x | P/E 2027 * | 6.06x |
|---|---|---|---|---|---|
| Enterprise Value | 5.96B 880M 769M 711M 664M 1.25B 83.17B 1.26B 8.45B 3.29B 40.89B 3.3B 3.23B 142B | EV / Sales 2026 * |
12.4x | EV / Sales 2027 * | 1.68x |
| Free-Float |
77.76% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: CStone Pharmaceuticals
| 1 day | +4.27% | ||
| 1 week | -1.60% | ||
| Current month | -40.22% | ||
| 1 month | -41.75% | ||
| 3 months | -29.37% | ||
| 6 months | -19.20% | ||
| Current year | -11.40% |
| 1 week | 0.48 |  | 0.51 |
| 1 month | 0.45 | | 0.86 |
| Current year | 0.45 | | 1.12 |
| 1 year | 0.44 | | 1.35 |
| 3 years | 0.09 | | 1.35 |
| 5 years | 0.09 | | 1.97 |
| 10 years | 0.09 | | 1.98 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jian Xin Yang
CEO | Chief Executive Officer | 62 | 2022-08-24 |
Wei Cong Ni
DFI | Director of Finance/CFO | - | 2023-01-17 |
Ying Hua Zhang
COO | Chief Operating Officer | 46 | 2016-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Wei Li
CHM | Chairman | 55 | - |
Jian Xin Yang
BRD | Director/Board Member | 62 | 2022-08-24 |
Edward Hu
BRD | Director/Board Member | 63 | 2021-07-08 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.27% | -1.60% | - | - | 944M | |
| +0.42% | -0.40% | +20.16% | -21.46% | 62.05B | |
| -0.84% | -4.48% | +57.21% | +196.38% | 54.52B | |
| -5.75% | +29.50% | +29.50% | +29.50% | 41.55B | |
| +2.09% | +8.49% | -52.13% | -59.12% | 39.06B | |
| +1.59% | +0.54% | +57.20% | -32.06% | 29.02B | |
| -7.22% | +13.84% | +129.13% | -50.74% | 25.38B | |
| +5.54% | +1.65% | +51.42% | +67.44% | 19.62B | |
| +3.32% | +1.83% | -1.39% | +155.50% | 16.89B | |
| +1.04% | +2.25% | +63.17% | +111.01% | 15.89B | |
| Average | +0.44% | +2.12% | +39.36% | +44.05% | 33.78B | |
| Weighted average by Cap. | -0.42% | +1.14% | +34.50% | +38.78% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 479M 70.76M 61.83M 57.2M 53.38M 100M 6.69B 101M 680M 264M 3.29B 266M 260M 11.42B | 1.71B 253M 221M 204M 191M 358M 23.9B 361M 2.43B 945M 11.75B 950M 929M 40.83B |
| Net income | -243M -35.91M -31.37M -29.02M -27.09M -50.85M -3.39B -51.22M -345M -134M -1.67B -135M -132M -5.8B | 687M 101M 88.68M 82.03M 76.56M 144M 9.59B 145M 975M 379M 4.72B 381M 373M 16.38B |
| Net Debt | -528M -77.98M -68.14M -63.03M -58.83M -110M -7.37B -111M -749M -291M -3.62B -293M -286M -12.59B | -3.6B -532M -465M -430M -401M -753M -50.27B -759M -5.11B -1.99B -24.72B -2B -1.95B -85.86B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-22 | 0.5050 € | +4.27% | 0 |
| 26-06-19 | 0.4843 € | -1.92% | 0 |
| 26-06-18 | 0.4938 € | +2.88% | 0 |
| 26-06-17 | 0.4800 € | -3.63% | 0 |
| 26-06-16 | 0.4981 € | -2.94% | 2,000 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 2616 Stock
- PH4 Stock
Select your edition
All financial news and data tailored to specific country editions
